Collecting biospecimens for cancer research
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Institutes of Health Clinical Center (CC) · NCT02682667
This study is collecting blood and tumor samples from adults with cancer to help researchers learn more about the disease and improve treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) (nih) |
| Drugs / interventions | Immunotherapy |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT02682667 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and bank various biospecimens, including blood and tumor samples, from adults diagnosed with cancer or pre-malignant conditions. Participants will undergo medical evaluations and provide samples for research to better understand cancer biology and treatment responses. The study will enroll up to 500 subjects and will not involve any investigational therapies. The collected samples will be used for nucleic acid, protein, and immunological studies to support immunotherapy research.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of cancer or a pre-malignant condition.
Not a fit: Patients with active medical or psychological illnesses that may increase risk, or those unable to provide informed consent, may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments tailored to individual patient responses.
How similar studies have performed: Other studies involving biospecimen collection for cancer research have shown success in advancing treatment strategies, indicating this approach is well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: 1. Diagnosis of cancer, a premalignant/neoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant/neoplastic condition 2. Age \>=18 years of age 3. ECOG performance status of 0-3. 5\. Ability and willingness of subject to provide informed consent Additional inclusion criteria pertinent only for participants undergoing apheresis 1. Hemoglobin \>= 8 mg/dL and platelet count \> 75 K/microL 2. Weight \>= 48 kg 3. Central line in place or adequate venous access EXCLUSION CRITERIA: 1. Active concomitant medical or psychological illnesses that may increase the risk to the subject. 2. Inability to provide informed consent 3. Pregnant or breastfeeding women
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: Scott M Norberg, D.O. — National Cancer Institute (NCI)
- Study coordinator: Scott M Norberg, D.O.
- Email: scott.norberg@nih.gov
- Phone: (301) 275-9668
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer, Apheresis Products, Immunological, Diverse Malignan